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The RNA modification N6-methyladenosine (m6A)
modulates mRNA fate and thus affects many biolog-
ical processes. We analyzed m6A across the tran-
scriptome following infection by dengue virus
(DENV), Zika virus (ZIKV), West Nile virus (WNV),
and hepatitis C virus (HCV). We found that infection
by these viruses in the Flaviviridae family alters m6A
modification of specific cellular transcripts, including
RIOK3 andCIRBP. During viral infection, the addition
of m6A to RIOK3 promotes its translation, while loss
of m6A in CIRBP promotes alternative splicing.
Importantly, viral activation of innate immune
sensing or the endoplasmic reticulum (ER) stress
response contributes to the changes in m6A in
RIOK3 or CIRBP, respectively. Further, several tran-
scripts with infection-altered m6A profiles, including
RIOK3 and CIRBP, encode proteins that influence
DENV, ZIKV, and HCV infection. Overall, this work
reveals that cellular signaling pathways activated
during viral infection lead to alterations in m6A modi-
fication of host mRNAs to regulate infection.
INTRODUCTION
Transcriptional and post-transcriptional regulatory mechanisms
influence gene expression in cells following infection by viruses,
including those in the Flaviviridae family. The Flaviviridae family of
positive-sense RNA viruses includes dengue virus (DENV), Zika
virus (ZIKV), West Nile virus (WNV), and hepatitis C virus (HCV),
all of which cause significant mortality and morbidity worldwide
(Holbrook, 2017; Thrift et al., 2017). Previous studies have shownbroad changes in cellular transcript levels during Flaviviridae
infection that highlight a complex relationship between viral
infection and gene expression, whereby the host attempts to
resist infection by up- or downregulating relevant genes while vi-
ruses co-opt host transcription to facilitate replication and avoid
host defenses (Fink et al., 2007; Kumar et al., 2016; Rosenberg
et al., 2018; Sessions et al., 2013; Su et al., 2002; Zanini et al.,
2018). Differential expression of proviral and antiviral host factors
is therefore an important determinant of the outcome of Flavivir-
idae infection.
Host gene expression during Flaviviridae infection can be
tuned by post-transcriptional RNA controls (De Maio et al.,
2016; Luna et al., 2015; Schwerk et al., 2015). One of these con-
trols is the chemical modification of RNA (Gilbert et al., 2016).
The most prevalent internal modification of mRNA is N6-methyl-
adenosine (m6A). The regulation of m6A in RNA is controlled by
specific cellular proteins. TheMETTL3-METTL14-WTAP ‘‘writer’’
complex catalyzes the methylation of adenosine residues in
mRNA, targeting the consensus motif DRA*CH (where D =
G/A/U, R = G/A, H = U/A/C, and * denotes modified A) in
mRNA for methylation; however, how specific DRACH motifs
are selected for modification is still not well understood (Meyer
and Jaffrey, 2017; Shi et al., 2019; Yang et al., 2018). ‘‘Reader’’
RNA-binding proteins recognize m6A to modulate mRNA meta-
bolism, including mRNA splicing, nuclear export, stability, trans-
lation, and structure (Meyer and Jaffrey, 2017; Shi et al., 2019;
Yang et al., 2018). By regulating specific transcripts, m6A affects
many important biological processes (Gonzales-van Horn and
Sarnow, 2017; Meyer and Jaffrey, 2017; Shi et al., 2019; Yang
et al., 2018).
Viral infection can be influenced by m6A modification of either
viral or host transcripts. Transcripts from both DNA and RNA vi-
ruses can be methylated, and m6A in these RNAs has various
proviral and antiviral functions (Courtney et al., 2017; Gokhale
et al., 2016; Gokhale and Horner, 2017; Hao et al., 2019; Imam
et al., 2018; Kennedy et al., 2016; Lichinchi et al., 2016a,
Figure 1. Flaviviridae Infection Alters m6A
Modification of Specific Transcripts
(A) Schematic of the MeRIP-seq protocol used to
identify differential m6A methylation following
infection of Huh7 cells with DENV, ZIKV, WNV, and
HCV. RNA was harvested at 48 h post-infection
(hpi), and experiments were performed in triplicate.
(B) The number of peaks and genes with m6A
peaks detected in R 2 mock- or virus-infected
samples (dark blue; MACS2 q value < 0.05) and
peaks that change during infection (light blue,
|peak – gene Log2FC| R 1, adjusted p < 0.05).
‘‘Infection-annotated genes’’: genes with known
annotations for the reactome pathways ‘‘infectious
disease,’’ ‘‘unfolded protein response,’’ ‘‘interferon
signaling,’’ or ‘‘innate immune signaling’’ in the
database used by fgsea. ‘‘Infection-regulated
genes’’: genes that show a Log2FC in gene
expressionR 2 in RNA expression betweenmock-
and virus-infected samples (adjusted p < 0.05).
(C) The most significantly enriched motif in
the MeRIP fractions across all samples (HOMER,
p = 1e-831).
(D) Metagene plot of ‘‘methylated’’ DRACH motifs
(detected in a peak in at least two replicates)
across transcripts in mock- and virus-infected
cells.
(E) The percent of genes with m6A peaks that changed expression with infection (|Log2FC| R 2, adjusted p < 0.05, N = 137) and genes that remained stable
(|Log2FC| < 0.5, adjusted p > 0.05, N = 7627) for transcripts with mean expression R 50 reads.
(F) (Left) MeRIP-qRT-PCR analysis of relative m6A level of transcripts with infection-altered m6A modification or controls (ACTB and MAVS) in DENV, ZIKV, and
HCV-infected (48 hpi) Huh7 cells. (Right) RNA expression of these transcripts relative toGAPDH. Values in heatmap are the mean of 3 independent experiments.
*p < 0.05, by unpaired Student’s t test.
See also Figure S1 and Tables S1 and S2.2016b; McIntyre et al., 2018; Rubio et al., 2018; Tirumuru et al.,
2016; Tsai et al., 2018; Williams et al., 2019; Winkler et al.,
2019; Ye et al., 2017). m6A in specific cellular transcripts is
also important during viral infection (Liu et al., 2019b; Rubio
et al., 2018; Winkler et al., 2019). For example, m6A regulates
the antiviral IFNB1 transcript (Rubio et al., 2018; Winkler et al.,
2019). However, the role of m6A in cellular mRNA during viral
infection is still not well understood, in part because of difficulties
in accurately and quantitatively mapping the modification. While
several viruses alter m6A modification in cellular mRNAs (Hesser
et al., 2018; Lichinchi et al., 2016a, 2016b; Tan et al., 2018), the
scale of these changes has likely been overestimated (McIntyre
et al., 2019). Moreover, there are almost no data on common
m6A changes in host mRNA across multiple viruses, and the
functional consequences of m6A changes in cellular mRNA dur-
ing viral infection have also not been examined. Therefore, iden-
tifying both m6A changes during viral infection and the conse-
quences of these changes on cellular mRNA are important for
understanding post-transcriptional regulation of the host
response to infection.
Here, we studied the effect of DENV, ZIKV, WNV, and HCV
infection on the m6A epitranscriptome. We found that infection
by all four viruses led to altered m6A modification of a set of spe-
cific cellular transcripts and that activation of innate immunity
and endoplasmic reticulum (ER) stress responses by infection
contribute to differential m6A modification and changes in trans-
lation or splicing of these transcripts. Importantly, transcripts
with altered m6A encode proteins that regulate infection, indi-cating that post-transcriptional gene regulation of mRNA by
m6A has the potential to affect host response and viral
replication.
RESULTS
Flaviviridae Infection Alters m6A Modification of
Specific Cellular Transcripts
Flaviviridae infection changes the expression of proviral and anti-
viral gene products (Fink et al., 2007; Kumar et al., 2016; Rosen-
berg et al., 2018; Sessions et al., 2013; Su et al., 2002; Zanini
et al., 2018). Since m6A can modulate RNA fate, and therefore
protein expression, we hypothesized that altered m6A modifica-
tion would influence expression of host genes that regulate viral
infection. We therefore measured changes in the m6A modifica-
tion of host transcripts during Flaviviridae infection using methyl-
ated RNA immunoprecipitation and sequencing (MeRIP-seq)
(Figure 1A). For MeRIP-seq, we used an anti-m6A antibody to
enrich m6A-modified RNA fragments prior to RNA sequencing
of both the input and immunoprecipitated (IP) fractions (Dominis-
sini et al., 2012; Meyer et al., 2012). We note that this antibody
also recognizes the similar modificationN6,2’-O-dimethyladeno-
sine (m6Am), which in mRNA is only found in the 5
0 cap (Linder
et al., 2015; Mauer and Jaffrey, 2018). We performed MeRIP-
seq on RNA from human Huh7 liver hepatoma cells, which are
permissive for all four viruses, at 48 h post-infection. At this
time point, 60%–90% of cells stained positive for viral antigen
(Figure S1A). We first identified gene expression changes in
response to infection. We analyzed differential expression of 
genes between infected samples and uninfected controls using 
the input fractions from MeRIP-seq and found 50 genes that 
were differentially expressed (DESeq2, adjusted p < 0.05, |Log2-
Fold Change (FC)| R 2) across all four viruses (Figures S1B and 
S1C; Table S1). We found that several pathways were similarly 
altered by all four viruses (Figure S1D), including innate immunity 
(such as NF-kB, TNF, and MAPK signaling) and the ER stress 
response. These results, which we validated by qRT-PCR (Fig-
ure S1E), are similar to what has been reported for individual Fla-
viviridae (Carletti et al., 2019; Fink et al., 2007; Kumar et al., 2016; 
Rosenberg et al., 2018; Sessions et al., 2013; Su et al., 2002; Za-
nini et al., 2018).
We then predicted m6A-modified regions within mRNAs by call-
ing peaks in IP over input RNA-seq coverage across transcripts 
using MACS2, a ChIP-seq peak caller commonly used to detect 
m6A peaks from MeRIP-seq data (McIntyre et al., 2019; Zhang 
et al., 2008). We detected a total of 31,647 peaks, with 25,852 
exonic peaks corresponding to 10,891 genes across all unin-
fected and infected samples (Figure 1B). The known m6A motif  
DRACH (in particular, GGACU) was enriched under the identified 
peaks (Figure 1C). As expected, detected peaks were most com-
mon at the end of the coding sequence and beginning of the 30 un-
translated region (UTR) (Figure 1D) (Meyer and Jaffrey, 2017). We 
did not observe a change in the distribution of m6A across tran-
script regions with DENV, ZIKV,WNV, or HCV infection (Figure 1D). 
This is in contrast to a previous report that suggested ZIKV infec-
tion led to increased methylation in the 50 UTRs of cellular tran-
scripts (Lichinchi et al., 2016b); however, we also did not detect 
a difference in m6A distribution in 50 UTRs following ZIKV infection 
on reanalysis of that published data using two different peak cal-
lers: MACS2 or MeTDiff (Figure S1F) (Cui et al., 2018). Further, 
following viral infection, we found only subtle changes in the over-
all level of m6A relative to unmodified adenosine in purified mRNA, 
as analyzed by liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) of digested nucleotides, and no change in the 
expression of cellular m6A machinery, as analyzed by immuno-
blotting (Figures S1G and S1H). Indeed, since the expression of 
the methylation machinery was not changed by infection, we 
would not predict broad, unidirectional changes in the abundance 
or distribution of m6A in cellular mRNAs.
However, functional annotation of the m6A-modified genes ex-
pressed in the infected samples did reveal an enrichment for 
genes with roles in infection. In total, 829 methylated genes 
were annotated as involved in the reactome pathways of 
‘‘infectious disease,’’ ‘‘unfolded protein response,’’ ‘‘interferon 
signaling,’’ or ‘‘innate immune system’’ (‘‘infection-annotated 
genes’’; see STAR Methods; Figure 1B). Further, 345 methylated 
genes were differentially expressed between infected and 
uninfected samples (‘‘infection-regulated genes’’; Figure 1B). 
Indeed, mRNAs that changed expression with infection 
(p adj < 0.05, |Log2FC| R 2, mean expression R 50) were 
more likely to have at least one m6A site than those that did 
not change expression (p adj > 0.05, |Log2FC| < 0.5, mean 
expression R 50; Fisher’s exact test p = 0.00074, odds ratio = 
0.64) (Figure 1E). These results support previous reports that 
transcripts that undergo dynamic regulation tend to contain 
more m6A sites than stable housekeeping mRNAs (Schwartzet al., 2014) and suggest that m6Amay regulate genes implicated
in infection.
We next determined changes in m6A from differences in IP
enrichment relative to gene expression with infection by all four
viruses. We detected shared m6A changes in 58 exonic peaks
in 51 genes following infection, most of which showed increases
inm6A andoccurred in the 30 UTRor coding sequence (Figure 1B;
Table S2). While differentially expressed genes were enriched for
pathways with known roles in infection (Figure S1D), genes that
showed changes in methylation did not show enrichment for
functional categories relevant to infection. We and others previ-
ously showed that MeRIP-qRT-PCR with primers under the
changed m6A peaks can detect relative changes in m6A (Engel
et al., 2018; McIntyre et al., 2019). Therefore, we used this
method to orthogonally validate 18 of the predicted m6A
changes following infection. In these and subsequent analyses,
we focused on m6A changes following DENV, ZIKV, and HCV
infection. Of these 18 transcripts, 16 showed a significant
change in m6A relative to any change in gene expression with
at least two viruses, and 9 of those showed a significant change
with all three viruses. Most non-significant m6A changes trended
toward the change predicted by MeRIP-seq (Figure 1F). ACTB
andMAVS mRNAs, both predicted to be stably methylated dur-
ing infection, indeed showed no m6A changes (Figure 1F).
For our predictions of pan-viral m6A changes using MeRIP-
seq (above), we compared all infected to all uninfected replicates
for increased statistical power (McIntyre et al., 2019). However,
to also detect any peak changes unique to single viruses, we
used the same computational approach described above (Table
S2). MeRIP-qRT-PCR for these putative virus-specific peaks
(two per virus) showed similar changes in relative m6A at those
peaks with infection by all three viruses tested, rather than indi-
vidual virus-mediated changes, in the same direction as pre-
dicted by MeRIP-seq (Figure S1I). This suggests that m6A
regulation can occur through common processes activated by
viral infection. Together, our data reveal that hundreds of tran-
scripts differentially expressed during Flaviviridae infection
containm6A and that infection altersm6Amodification of specific
host transcripts.
Flaviviridae Infection Alters m6A Modification of RIOK3
and CIRBP mRNA through Distinct Pathways
We focused on two specific transcripts that gain and lose m6A
(RIOK3 and CIRBP, respectively) during infection by all viruses
for further analysis. RIOK3 encodes a serine/threonine kinase
that may regulate antiviral signaling (Feng et al., 2014; Taka-
shima et al., 2015; Willemsen et al., 2017), while CIRBP encodes
a stress-induced RNA-binding protein (Liao et al., 2017).
Following viral infection, RIOK3 mRNA gains an m6A peak in
the 30 UTR near the stop codon (Figure 2A), and CIRBP mRNA
loses an m6A peak in the coding sequence of its last exon (Fig-
ure 2B). The RIOK3 and CIRBP peaks span four and three
DRACHmotifs, respectively. Both peaks appear in published da-
tasets: the RIOK3 peak in mouse liver tissue (Zhou et al., 2018)
and the CIRBP peak in HepG2 cells (Huang et al., 2019; Zhong
et al., 2018). We performed MeRIP-qRT-PCR on RNA from cells
infected with DENV, ZIKV, and HCV to validate these m6A
changes. MeRIP-qRT-PCR confirmed that the relative m6A
Figure 2. Flaviviridae Infection Alters m6A Modification of RIOK3 and CIRBP mRNA through Distinct Cellular Pathways
(A and B) Coverage plot of MeRIP (color) and input (black) reads in (A) RIOK3 and (B) CIRBP transcripts in Huh7 cells infected with the indicated virus (48 hpi), as
determined by MeRIP-seq. Representative of three biological replicates. Infection-altered m6A peaks are indicated in black under the transcript map.
(C) (Left) MeRIP-qRT-PCR analysis of relativem6A level ofRIOK3 andCIRBP in mock- and virus-infected (48 hpi) Huh7 cells. (Right) RNA expression ofRIOK3 and
CIRBP relative to HPRT1.
(D) (Left) MeRIP-qRT-PCR analysis of relative m6A level of RIOK3 and CIRBP in mock- and HCV PAMP-transfected (8 h) Huh7 cells. (Right) RNA expression of
RIOK3, CIRBP, as well as positive control transcripts IFNB1 and IFIT1 relative to HPRT1.
(E) (Left) MeRIP-qRT-PCR analysis of relative m6A level of RIOK3 and CIRBP in mock- and thapsigargin-treated (TG; 16 h) Huh7 cells. (Right) RNA expression of
RIOK3, CIRBP, and positive control transcripts HSPA5 and XBP1 relative to HPRT1. Values are the mean ± SEM of 6 (C and D), or 5 (E) biological replicates. *p <
0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t test. ns, not significant.
See also Figure S2 and Tables S2 and S3.modification of RIOK3 was significantly increased and that of
CIRBP decreased after infection, while RIOK3 and CIRBP
mRNA levels both increased (Figures 1F and 2C). These m6A
changes in RIOK3 and CIRBP were also apparent in chro-
matin-associated RNA following ZIKV infection, suggesting
that the regulation of m6A at these sites occurs co-transcription-
ally (Ke et al., 2017; Slobodin et al., 2017) (Figure S2A). In
uninfected cells, both RIOK3 and CIRBP transcripts are
bound by the m6A-binding protein YTHDF1 (Figures S2B and
S2C). However, DENV, ZIKV, and HCV infection increased
YTHDF1 association with RIOK3 and decreased its association
with CIRBP, suggesting that YTHDF1 recognizes the alteredm6A status of RIOK3 and CIRBP transcripts following infection
(Figure S2D).
We next investigated whether cellular pathways stimulated by
viral infection (Figure S1D) contribute to the virally induced m6A
changes in RIOK3 and CIRBP. Flaviviridae infection drives
signaling cascades that lead to the induction of interferon-b
(IFN) and antiviral IFN-stimulated genes (ISGs) by IRF3 (Horner
and Gale, 2013; Muñoz-Jordán and Fredericksen, 2010; Suthar
et al., 2013). In infected Huh7 IRF3 KO cells (Vazquez et al.,
2019), the increase in RIOK3 m6A with infection was attenuated
(from 4- to 1.5-fold) compared to parental cells (Figures S2E
and 2C). However, DENV and ZIKV infection of IRF3 KO cells still
 
reduced the relative m6A enrichment of CIRBP, consistent with 
that seen following infection of the parental cells (Figures S2E 
and 2C) (Vazquez et al., 2019). This suggests that IRF3 activation 
contributes to increased RIOK3 m6A modification while not 
affecting the m6A status of CIRBP. To determine if innate im-
mune activation in the absence of replicating virus alters m6A 
modification of RIOK3 and CIRBP, we measured the relative 
m6A levels of RIOK3 and CIRBP mRNA by MeRIP-qRT-PCR 
following transfection of Huh7 cells with an HCV immunostimu-
latory RNA (HCV PAMP) (Saito et al., 2008). HCV PAMP induced 
expression of IFNB1 and the ISG IFIT1 and also increased m6A 
modification of RIOK3 but did not decrease CIRBP methylation 
(Figure 2D). Importantly, we found that the increase in RIOK3 
m6A following HCV PAMP was dependent on the m6A methyl-
transferases METTL3 and METTL14, as HCV PAMP did not in-
crease m6A modification of RIOK3 following depletion of 
METTL3 and METTL14 (Figure S2F). IFN-b treatment, which ac-
tivates the IFN response, also led to a slight but significant in-
crease in the relative m6A enrichment of RIOK3 but not CIRBP 
(Figure S2G). These data indicate that signaling through innate 
immune sensing and response pathways promotes the m6A 
modification of RIOK3 mRNA following infection.
We next sought to define the signaling pathways that lead to 
reduced m6A modification of CIRBP mRNA. We and others 
have shown that Flaviviridae infection activates the ER stress 
response (Figure S1D) (Blá zquez et al., 2014; Carletti et al., 
2019; Chan, 2014; Neufeldt et al., 2018). To test whether ER 
stress alters the m6A modification of CIRBP or RIOK3, we
measured their relative m6A levels following treatment of cells 
with thapsigargin (TG; Figure 2E), an ER Ca2+ ATPase inhibitor 
that induces an ER stress response (Lee et al., 2012). TG 
increased the mRNA level of both RIOK3 and CIRBP and that 
of the positive controls HSPA5 and XBP1 by about 4-fold (Fig-
ure 2E). Further, TG reduced m6A modification of CIRBP, similar 
to what we observed with viral infection, while not changing the 
relative m6A level of RIOK3 (Figure 2E). Together, these data 
reveal that innate immune and ER stress signaling, both of which 
are activated during Flaviviridae infection, can divergently influ-
ence the m6A methylation program and can separately affect 
m6A modification of specific transcripts.
To define the mRNAs that have altered m6A in response to 
innate immune or ER stress signaling, we also performed 
MeRIP-seq analysis on mRNA from Huh7 cells treated with 
HCV PAMP or TG. Both of these treatments led to m6A peak 
changes in a subset of mRNAs (Figure S2H; Table S3). The 
m6A peaks detected in these data did not necessarily corre-
spond to peaks called in the infection data (Table S2), likely 
because the reproducibility of individual MeRIP-seq peaks is 
low (McIntyre et al., 2019). Therefore, we calculated differences 
in m6A enrichment with HCV PAMP and TG at the 31,467 
regions previously identified as m6A peaks in the infection data 
(|Log2FC > 1| and threshold of p < 0.1). We observed five infec-
tion-altered peaks that were also changed by TG, including the 
CIRBP peak, and three infection-altered peaks also changed 
with HCV PAMP (Figure S2I). All of these changes were in the 
same direction as observed with infection. The infection-induced 
m6A peak in RIOK3 did show an increase in m6A enrichment at 
the same region with HCV PAMP, but it was not statistically sig-nificant, perhaps because the m6A changes observed with HCV
PAMP were smaller than those observed with infection (Figures
2C and 2D). These results reveal that innate immune and ER
stress signaling drive a portion of the m6A changes we observed
during Flaviviridae infection.
m6A Modification Enhances RIOK3 Protein Expression
during Infection
We next investigated the function of m6A in RIOK3mRNA during
infection. Consistent with our finding that DENV, ZIKV, and HCV
infection all increased RIOK3 mRNA levels (Figure 2C), RIOK3
protein expression also increased following infection (Figure 3A).
m6A can alter mRNA nuclear export, stability, and translation, all
of which could regulate protein expression (Meyer and Jaffrey,
2017; Yang et al., 2018). We found no significant change in the
nuclear export or mRNA stability of RIOK3 during infection (Fig-
ures S3A and S3B). However, we did detect increased nascent
translation of RIOK3 in DENV-infected cells compared to unin-
fected cells as measured by 35S labeling of nascent proteins fol-
lowed by RIOK3 protein immunoprecipitation, suggesting that
RIOK3 translation was increased by infection (Figure 3B). This
is consistent with our finding that during infection RIOK3
mRNA has increased binding to them6A reader protein YTHDF1,
which can promote translation of bound mRNAs under specific
conditions (Figure S2D) (Han et al., 2019; Shi et al., 2018;
Wang et al., 2015, 2019). To directly test whether YTHDF1 pro-
motes RIOK3 translation, we measured RIOK3 protein levels
following DENV infection in cells depleted of YTHDF1. We found
that YTHDF1 depletion prevented the DENV-induced increase
in RIOK3 protein expression (Figure 3C). RIOK3 translation
increased during Flaviviridae infection, even though these vi-
ruses generally inhibit global cellular translation and induce the
phosphorylation of the eukaryotic translation initiation factor
eIF2a (Figure S3C) (Arnaud et al., 2010; Garaigorta and Chisari,
2009; Roth et al., 2017; Stern-Ginossar et al., 2019; Wek,
2018). Therefore, our results suggest that m6A modification of
RIOK3 could allow this transcript to be efficiently translated dur-
ing infection in a YTHDF1-dependent manner, despite global in-
hibition of translation.
To directly test whether m6A can promote RIOK3 protein
expression during infection, we generated Huh7 cell lines stably
expressing a luciferase reporter that contains the wild-type (WT)
RIOK3 30 UTR, or an analogous 30 UTR sequence in which all pu-
tative m6A sites were abrogated by A/T mutations (m6A-mut),
downstream of a Renilla luciferase gene in which all DRACHmo-
tifs were ablated (m6A null) (Figure 3D). These constructs also ex-
pressed a m6A null Firefly luciferase gene whose expression is
not regulated by m6A. The WT RIOK3 reporter had increased
m6A modification compared to the m6A-mut RIOK3 reporter
following viral infection, as measured by MeRIP-qRT-PCR using
primers that specifically amplified reporter RNA (Figure 3E).
Therefore, theRIOK3 30 UTR sequence is sufficient for m6A addi-
tion following infection. Importantly, the relative luciferase activ-
ity of the WT RIOK3 reporter was significantly increased
compared to the m6A-mut reporter following viral infection (Fig-
ure 3F). Taken together, these data reveal that m6A modification
of the 30 UTR of RIOK3 during infection promotes its translation
during infection.
Figure 3. m6A Promotes RIOK3 Protein Expression
(A) (Left) Representative immunoblot of RIOK3 protein expression in mock-
and virus-infected (48 hpi) Huh7 cells. (Right) Quantification of RIOK3 protein
expression relative to tubulin.
(B) Immunoprecipitation (IP) of RIOK3 from mock- and DENV-infected (48 hpi)
Huh7 cells labeled with 35S for 3 h. IP fractions were analyzed by autoradi-
ography (35S) and immunoblotting. Representative of 3 biological replicates.
(C) (Left) Representative immunoblot of RIOK3 protein expression in mock-
and DENV-infected (48 hpi) Huh7 cells treated with non-targeting control
(CTRL) or YTHDF1 siRNA. (Right) Quantification of RIOK3 protein expression
relative to tubulin.
(D) Schematic of WT and mutant m6A null Renilla luciferase (RLuc) RIOK3 30
UTR reporters that also express m6A null Firefly luciferase (FLuc) from a
separate promoter. qRT-PCR primers (F and R) are indicated with arrows.
(E) MeRIP-qRT-PCR analysis of relative m6A level of stably expressed WT and
m6A-mut RIOK3 30 UTR reporter RNA in mock- and virus-infected (48 hpi)
Huh7 cells.
(F) Relative luciferase activity (RLuc/FLuc) in mock- and virus-infected (48 hpi)
Huh7 cells stably expressing WT and m6A-mut RIOK3 30 UTR reporters.
Relative luciferase activity in uninfected cells was set as 1 for each reporter.
Values are themean ±SEMof 6 (A), 4 (C), 2 (E), or 5 (F) biological replicates. *p <
0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t test. ns, not significant.
See also Figure S3.m6A Modification Promotes Alternative Splicing of
CIRBP mRNA during Infection
We then analyzed the function of reduced m6A modification in
CIRBP mRNA following infection. Neither the nuclear export
nor the stability of CIRBP mRNA were affected following infec-
tion, suggesting that the loss of m6A in CIRBP does not regulate
these processes (Figures S4A and S4B). Based on our RNA-seq
data, CIRBP encodes at least 2 isoforms: (1) the dominant, short
isoform (CIRBP-S), which encodes a 172 aa, 18 kDa protein and
(2) a long isoform in which an intron immediately downstream of
the infection-altered m6A peak and upstream of the stop codon
is retained (CIRBP-L), resulting in a 297 aa, 32 kDa protein (Fig-
ure 4A; retained intron referred to as alternatively spliced region
[ASR]). Interestingly, analysis of our RNA-seq data using MAJIQ
(Vaquero-Garcia et al., 2016) to identify local splice variants sug-
gested decreased retention of this intron during infection, which
we confirmed in infected cells using qRT-PCR (Figure 4B). We
observed a similar reduction of intron retention following TG
treatment, which we had found also reduces CIRBP m6A modi-
fication (Figures 4C and 2F). Indeed, both viral infection and TG
treatment significantly reduced the protein level of CIRBP-L con-
taining the retained intron, without affecting expression of
CIRBP-S (Figures 4D and 4E). To test whether reduction of
m6A modification at the m6A peak in CIRBPmight affect alterna-
tive splicing of this transcript, we generated a splicing reporter
wherein the m6A null Renilla luciferase gene was fused to the
WT genomic sequence of CIRBP from exon 5 onward (WT
CIRBP) and a corresponding reporter in which the putative
m6A sites in the identified CIRBP m6A peak were synonymously
mutated (m6A-mut CIRBP) (Figure 4F). Using qRT-PCR, we
found that the m6A-mut reporter had reduced intron retention
compared to the WT reporter, revealing that the loss of m6A in
CIRBP regulates its alternative splicing and reduces the expres-
sion of the long isoform (Figure 4G).
To understand the purpose of alternative isoform usage of
CIRBP during infection, we measured the polysome occupancy
of the twoCIRBP isoforms in response to infection. As expected,
due to the global translation suppression known to occur during
DENV (Roth et al., 2017), the size of the 80S peak was increased
and polysomal peaks were decreased in DENV-infected cells
(Figure S4C). CIRBP-L was not found in heavy polysome frac-
tions in either uninfected or DENV-infected cells, suggesting
that this transcript is inefficiently translated (Figure S4D). In
contrast, CIRBP-S was found in heavy polysome fractions, but
this associationwas reducedduringDENV infection (FigureS4D).
This suggests that CIRBP-S has reduced translation during
infection. Given that the protein expression of CIRBP-S is not
significantly reduced during infection (Figure 4D), reducing the
expression of the inefficiently translated CIRBP-L isoform may
represent a mechanism to ensure consistent production of
CIRBP protein during viral infection.
m6A-Altered Genes Regulate Flaviviridae Infection
Having found that both RIOK3 and CIRBP transcripts have
altered m6A modification during infection, we tested whether
their encoded protein products affect Flaviviridae infection. We
depleted RIOK3 and CIRBP in Huh7 cells, infected these cells
with DENV, ZIKV, or HCV, and then measured viral titer in the
Figure 4. m6A Promotes Alternative Splicing of CIRBP
(A) Schematic of CIRBP transcript isoforms with a focus on the alternatively spliced region (ASR). qRT-PCR primer locations are indicated with arrows (FC-RC:
control CIRBP amplicon; F-RL: long isoform specific; F-RS: short isoform specific.
(B) qRT-PCR analysis of short (S) and long (L) CIRBP RNA isoforms in mock- and virus-infected (48 hpi) Huh7 cells relative to control CIRBP amplicon.
(C) qRT-PCR analysis of S and L CIRBP RNA isoforms in mock- and TG-treated (16 h) Huh7 cells.
(D) (Left) Representative immunoblot of short (CIRBP-S) and long (CIRBP-L) CIRBP protein isoforms in mock- and virus-infected (48 hpi) Huh7 cells. (Right)
Quantification of CIRBP protein isoform expression relative to tubulin.
(E) (Left) Representative immunoblot analysis of CIRBP protein isoforms in mock- and TG-treated (500 nM, 16 h) Huh7 cells. HSPA5 and GADD34 are positive
controls. (Right) Quantification of CIRBP protein isoform expression relative to tubulin.
(F) Schematic ofWT andm6A-mutCIRBP splicing reporters. qRT-PCR primer locations (Fluc-Rluc: control; F-RL: long isoform specific; F-Rs: short isoform specific)
are indicated with arrows.
(G) qRT-PCR analysis of CIRBP splicing reporter isoform expression (S and L) relative to control RLuc amplicon in Huh7 cells transfected with WT and m6A-mut
constructs. Values are the mean ± SEM of 3 (B, D, E, G) or 5 (C) biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t test. ns, not
significant.
See also Figure S4.supernatant. siRNA treatment reduced both RIOK3 and CIRBP 
mRNA levels by 70% and did not affect cell viability (Figures 
S5A and S5B). We found that RIOK3 depletion significantly 
reduced the production of infectious DENV and ZIKV particles 
but increased the production of infectious HCV particles (Fig-
ure 5A). Consistent with these data, RIOK3 stably overexpressed 
in two different clonal cell lines had the opposite effect on DENV, 
ZIKV, and HCV infectious particle production (Figures 5B and5C). This suggests that RIOK3 promotes DENV and ZIKV infec-
tion but inhibits HCV infection. However, the depletion of both
the large and small isoforms of CIRBP, as well as only the large
isoform of CIRBP, reduced the production of infectious DENV,
ZIKV, and HCV (Figures 5D, S5C, and S5D), while overexpres-
sion of both the short and long isoforms of CIRBP in two different
clonal cell lines each increased infection by these viruses (Fig-
ures 5E and 5F). This suggests that both CIRBP isoforms are
Figure 5. RIOK3 and CIRBP Regulate Flavi-
viridae Infection
(A) Focus-forming assay (FFA) of supernatants
from DENV, ZIKV, or HCV-infected (72 hpi) Huh7
cells treated with non-targeting control (CTRL) or
RIOK3 siRNA.
(B) FFA of supernatants from DENV, ZIKV, or HCV-
infected (72 hpi) Huh7 cells stably overexpressing
FLAG-GFP or FLAG-RIOK3 (2 independent
clones).
(C) Immunoblot analysis of cell lines in (B).
(D) FFA of supernatants harvested from DENV,
ZIKV, or HCV-infected (72 hpi) Huh7 treated with
CTRL or CIRBP siRNA.
(E) FFA of supernatants from DENV, ZIKV, or HCV-
infected (72 hpi) Huh7 cells stably overexpressing
FLAG-GFP or the short (FLAG-CIRBP-S) or long
(FLAG-CIRBP-L) isoforms of CIRBP (2 indepen-
dent clones).
(F) Immunoblot analysis of cell lines in (C). Values
are themean ± SEM of 4 (A and D) or 3 (B, E, and G)
biological replicates. Viral infections were per-
formed at amultiplicity of infection of 0.2. *p < 0.05,
**p < 0.01, ***p < 0.001 by unpaired Student’s
t test. ns, not significant.
See also Figure S5.proviral during DENV, ZIKV, and HCV infection. Interestingly, the
CIRBP-S protein resides primarily in the nucleus, while CIRBP-L
is predominantly cytoplasmic, irrespective of viral infection,
which implicates distinct spatial regulation of proviral activity
by CIRBP isoforms (Figure S5E).
We then performed a targeted siRNA screen to test whether
other transcripts with infection-altered m6A modification affect
Flaviviridae infection. We depleted transcripts in which we had
identified m6A changes during infection (Figures 1F and S1I); in-
fected these cells with DENV, ZIKV, or HCV; and measured cell
viability, relative to RNA depletion levels, and the production of
infectious virions in the supernatant (Figures 6 and S6A–S6C).
We focused only on those transcripts that were depleted by at
least 40% in our further analysis (21 out of 24 tested). For these,
we found that 18/21 (86%) regulate at least one virus, while 10/
21 (48%) affect at least two and 6/21 (29%) regulate all three vi-
ruses. For each virus, 50% of m6A-altered transcripts that we
tested significantly increased or decreased infection. This indi-
cates that m6A can, as a general principle, tune the outcome
of infection by modifying specific transcripts that regulate
infection.
DISCUSSION
Here, we identify changes in m6A methylation of cellular mRNAs
during infection by viruses in the Flaviviridae family. We observed
that infection by DENV, ZIKV,WNV, and HCV leads to changes in
m6A of a specific set of cellular transcripts, including some that
encode factors that modulate Flaviviridae infection. We found
that virus-induced pathways, including innate immune signaling
and ER stress signaling, contribute to altered m6A of several of
these transcripts. Taken together, this work suggests that m6A
changes induced through cellular signaling pathways influence
Flaviviridae infection.We identified hundreds of m6A-modified transcripts that were
differentially expressed during infection or that were annotated
as part of cellular pathways relevant for infection. These findings
suggest that m6A has the potential to post-transcriptionally regu-
late many genes during infection. Here, we focused on specific
transcripts with virus-induced m6A changes; we identified 58
peak changes in 51 transcripts following infection by DENV,
ZIKV, WNV, and HCV. As our m6A change analysis pipeline con-
trols for changes in gene expression (McIntyre et al., 2019), these
data should represent true changes in m6A modification rather
than changes in the expression of m6A-modified transcripts.
While changes in both m6A modification and the expression of
m6A-modified transcripts are biologically relevant, identifying
bona fidem6A alterations during viral infection will allow us to un-
derstand how m6A modification of cellular mRNA is regulated.
We found that the changes in m6A methylation of RIOK3,
CIRBP, and several other transcripts are driven by innate
immune induction and the cellular response to ER stress,
respectively. This suggests that these signals and likely other
infection-induced pathways can be integrated into differential
m6A methylation activity and ultimately affect m6A modification
of cellular mRNAs. While expression changes in m6A machinery
affect m6A modification during cancer and infection (Barbieri
et al., 2017; Li et al., 2017b; Lin et al., 2016; Rubio et al., 2018;
Vu et al., 2017; Winkler et al., 2019), this machinery did not
change expression with Flaviviridae infection, pointing to a
different mechanism for altered m6A modification. Going for-
ward, identifying the molecular mechanisms through which
these signaling pathways lead to differential m6A will be an
important advance in understanding how the m6A machinery
acts on specific sites.
Our data suggest that virus-induced m6A changes occur in
nascent mRNA, which supports the hypothesis that m6A is
added co-transcriptionally and does not dynamically change
Figure 6. Genes with Infection-Induced m6A Alterations Regulate 
Flaviviridae Infection
Heatmap of viral titers of supernatants harvested from DENV, ZIKV, or HCV-
infected cells (48 hpi) treated with the indicated siRNAs. Data are presented as 
percentage of titer of each virus relative to cells treated with CTRL siRNA. 
Colors represent the mean of 3 biological replicates. Viral infections were 
performed at a multiplicity of infection of 0.2. *p < 0.05 by unpaired Student’s 
t test.
See also Figure S6.after export to the cytoplasm (Ke et al., 2017). At least three pro-
cesses could modulate the selective m6A modification of spe-
cific transcripts during transcription. First, novel interactions of
the m6A writers METTL3 and METTL14 with viral-induced or
stress-regulated RNA-binding proteins could target these
writers to specific mRNAs and lead to m6A changes during infec-
tion. For example, RBM15/15B and VIRMA can target the m6Amethyltransferase complex to Xist long non-coding RNA or to
the 30 UTRs of mRNA, respectively (Patil et al., 2016; Yue et al.,
2018). Second, the writers could be recruited to nascent mRNAs
by the histone modification H3K36me3, which marks transcrip-
tionally active loci and recruits METTL14 (Huang et al., 2019).
Intriguingly, in HepG2 cells, the CIRBP locus is marked by
H3K36me3, and its transcript contains an m6A peak at the
same site that we identified in Huh7 cells (Huang et al., 2019).
This suggests that infection- or ER stress-induced depletion of
H3K36me3 marks at the CIRBP locus could result in reduced
m6A ofCIRBP byMETTL3 andMETTL14. Third, changes in tran-
scription rates, which have been inversely correlated with m6A
deposition in mRNA, could also contribute to m6A modification
of specific transcripts during infection (Slobodin et al., 2017).
Further, viral infection can affect RNA structure in cellular tran-
scripts; it is possible that altered mRNA structure could result
in divergent m6A modification of cellular transcripts during infec-
tion (Mizrahi et al., 2018). Perturbing cellular homeostasis by
infection therefore has the potential to reveal new insights into
the regulation of m6A modification of cellular transcripts.
We hypothesize that during viral infection, m6A regulation of
RNA metabolism leads to rapid, tunable changes in mRNA and
protein abundance of host factors. While m6A can affect
mRNA nuclear export and stability, Flaviviridae infection did
not affect these processes for either RIOK3 or CIRBP mRNA.
Instead, we found that m6A changes promote translation of
RIOK3 and alternative splicing of CIRBP. m6A promotes transla-
tion of modified mRNAs in multiple contexts by mediating
interactions with m6A-binding proteins, including YTHDF1 (Edu-
puganti et al., 2017; Han et al., 2019; Huang et al., 2018; Li et al.,
2017a; Lin et al., 2016; Meyer et al., 2015; Shi et al., 2017, 2018;
Wang et al., 2015, 2019). Similarly, the interaction of YTHDF1
with RIOK3 mRNA during infection promoted RIOK3 translation
even in the context of eIF2a phosphorylation and suppression
of global translation (Arnaud et al., 2010; Garaigorta and Chisari,
2009; Roth et al., 2017). ForCIRBP, the loss ofm6A following viral
infection led to reduced expression of its long isoform. m6A reg-
ulates splicing by modulating mRNA interactions with several
m6A-binding splicing factors, which suggests that the loss of
m6A in CIRBP regulates alternative splicing through changes in
its interactions with splicing factors (Alarcón et al., 2015; Liu
et al., 2015, 2017b; Louloupi et al., 2018; Xiao et al., 2016; Ye
et al., 2017; Zhao et al., 2014; Zhou et al., 2019). Interestingly,
CIRBP-L is not translated as efficiently as CIRBP-S; therefore,
reducing the relative abundance of the long isoform might be
an expeditious mechanism to maintain abundant CIRBP protein
levels during cellular stress. How m6A regulates the fate of other
mRNAs with altered modification is still unknown, but it is
possible that m6A post-transcriptionally affects the abundance
of their protein products or splicing isoforms, similar to how it
regulates RIOK3 and CIRBP.
RIOK3 promoted DENV and ZIKV infection but inhibited HCV.
Interestingly, RIOK3 can both positively and negatively regulate
innate immune responses by either stimulating the interaction
between TBK1 and IRF3 or by phosphorylating and inactivating
MDA5 (Feng et al., 2014; Shan et al., 2009; Takashima et al.,
2015; Willemsen et al., 2017). The differences in the effects of
RIOK3 on DENV, ZIKV, and HCV infection could reflect the
different strategies used by these viruses to inhibit host immune
responses (Chen et al., 2017; Gack and Diamond, 2016; Gokhale
et al., 2014). Further, Willemsen et al. found that while RIOK3
enhanced innate immune activation, it also promoted influenza
A virus infection, implying that RIOK3 could have roles in infec-
tion beyond innate immunity (Willemsen et al., 2017).
Both CIRBP isoforms were proviral for DENV, ZIKV, and HCV.
The biological functions of the individual CIRBP isoforms, which
we found have different subcellular localizations, remain un-
known. CIRBP can modulate the translation of pro-inflammatory
factors and have anti-apoptotic effects in response to various
stresses (Liao et al., 2017). During infection, reduction in the
long isoform of CIRBP through loss ofm6A could inhibit infection,
suggesting that this loss of m6A during infection is part of the
host response to infection. Alternatively, reduction of the poorly
translated long isoform of CIRBPmRNAmay be a normal part of
the cellular stress response to ensure robust production of
CIRBP protein, which can then be co-opted by Flaviviridaemem-
bers to facilitate their replication.
Overall, transcripts with altered m6A modification during Flavi-
viridae infection encoded proteins that influenced the outcome
of infection. For each virus, approximately half of the factors
tested showed either proviral or antiviral effects, while 86%
affected the titer of at least one virus. These data suggest that
m6A itself does not represent a simple proviral or antiviral mech-
anism during infection but rather distinctly modulates specific
transcripts that ultimately affect the outcome of infection by
different members of the Flaviviridae family.
The scale of m6A epitranscriptomic changes with virus infec-
tion varies greatly among previous reports (Hesser et al., 2018;
Lichinchi et al., 2016a; Rubio et al., 2018; Tan et al., 2018; Win-
kler et al., 2019). Although we identified altered m6A in 58 peaks
in 51 transcripts during infection, inherent variance in transcript
coverage in MeRIP-seq data means that many replicates are
necessary for statistically significant detection of m6A changes
(McIntyre et al., 2019). In particular, this means that our analysis
(n = 3 per virus) may underestimate the total number of virus-
specific, altered m6A peaks. Additionally, we used a more con-
servative statistical approach than many previous studies to
reveal only the most robust peak changes (McIntyre et al.,
2019). The changes detected in MeRIP-seq peaks were vali-
dated using MeRIP-qRT-PCR; however, these data do not
provide the precise ratio of modified to unmodified copies of a
transcript or the exact nucleotides that are modified. Biochem-
ical assays like SCARLET or new sequencing methods will be
necessary to resolve this question (Liu et al., 2019a; Saletore
et al., 2012).
In summary, we found that Flaviviridae infection leads to m6A
changes in transcripts that can influence viral infection. We iden-
tified innate immune activation and the ER stress response as
signals that can modulate m6A levels in specific cellular mRNAs.
Our work indicates that post-transcriptional regulation of spe-
cific transcripts by m6A and other RNA modifications can be
an important determinant of the outcome of infection. Indeed,
viral infection alters the abundance of several other epitranscrip-
tomic modifications on cellular RNA (McIntyre et al., 2018),
revealing that we are only beginning to understand how RNA
modifications affect viral infection.STAR+METHODS
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M., Bé dard, N., Bruneau, J., Rice, C.M., and Shoukry, N.H. (2018). 
Longitudinal transcriptomic characterization of the immune response to acute 
hepatitis C virus infection in patients with spontaneous viral clearance. PLoS 
Pathog. 14, e1007290.
Roth, H., Magg, V., Uch, F., Mutz, P., Klein, P., Haneke, K., Lohmann, V., 
Bartenschlager, R., Fackler, O.T., Locker, N., et al. (2017). Flavivirus Infection 
Uncouples Translation Suppression from Cellular Stress Responses. MBio 8, 
e02150–16.
Rubio, R.M., Depledge, D.P., Bianco, C., Thompson, L., and Mohr, I. (2018). 
RNA m6 A modification enzymes shape innate responses to DNA by regulating 
interferon b. Genes Dev. 32, 1472–1484.
Saito, T., Owen, D.M., Jiang, F., Marcotrigiano, J., and Gale, M., Jr. (2008). 
Innate immunity induced by composition-dependent RIG-I recognition of hep-
atitis C virus RNA. Nature 454, 523–527.
Saletore, Y., Meyer, K., Korlach, J., Vilfan, I.D., Jaffrey, S., and Mason, C.E.
(2012). The birth of the Epitranscriptome: deciphering the function of RNA 
modifications. Genome Biol. 13, 175.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, 
T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an 
open-source platform for biological-image analysis. Nat. Methods 9, 676–682.
Schwartz, S., Mumbach, M.R., Jovanovic, M., Wang, T., Maciag, K., Bushkin, 
G.G., Mertins, P., Ter-Ovanesyan, D., Habib, N., Cacchiarelli, D., et al. (2014). 
Perturbation of m6A writers reveals two distinct classes of mRNA methylation 
at internal and 50 sites. Cell Rep. 8, 284–296.
Schwerk, J., Jarret, A.P., Joslyn, R.C., and Savan, R. (2015). Landscape of 
post-transcriptional gene regulation during hepatitis C virus infection. Curr. 
Opin. Virol. 12, 75–84.
Sergushichev, A.A. (2016). An algorithm for fast preranked gene set enrich-
ment analysis using cumulative statistic calculation. bioRxiv. https://doi.org/ 
10.1101/060012.
Sessions, O.M., Barrows, N.J., Souza-Neto, J.A., Robinson, T.J., Hershey, 
C.L., Rodgers, M.A., Ramirez, J.L., Dimopoulos, G., Yang, P.L., Pearson, 
J.L., and Garcia-Blanco, M.A. (2009). Discovery of insect and human dengue 
virus host factors. Nature 458, 1047–1050.
Sessions, O.M., Tan, Y., Goh, K.C., Liu, Y., Tan, P., Rozen, S., and Ooi, E.E.
(2013). Host cell transcriptome profile during wild-type and attenuated dengue 
virus infection. PLoS Negl. Trop. Dis. 7, e2107.
Shan, J., Wang, P., Zhou, J., Wu, D., Shi, H., and Huo, K. (2009). RIOK3 inter-
acts with caspase-10 and negatively regulates the NF-kappaB signaling 
pathway. Mol. Cell. Biochem. 332, 113–120.
Shi, H., Wang, X., Lu, Z., Zhao, B.S., Ma, H., Hsu, P.J., Liu, C., and He, C.
(2017). YTHDF3 facilitates translation and decay of N6-methyladenosine-
modified RNA. Cell Res. 27, 315–328.
Shi, H., Zhang, X., Weng, Y.L., Lu, Z., Liu, Y., Lu, Z., Li, J., Hao, P., Zhang, Y., 
Zhang, F., et al. (2018). m6A facilitates hippocampus-dependent learning and 
memory through YTHDF1. Nature 563, 249–253.
Shi, H., Wei, J., and He, C. (2019). Where, When, and How: Context-
Dependent Functions of RNA Methylation Writers, Readers, and Erasers. 
Mol. Cell 74, 640–650.
Slobodin, B., Han, R., Calderone, V., Vrielink, J., Loayza-Puch, F., Elkon, R., 
and Agami, R. (2017). Transcription Impacts the Efficiency of mRNA 
Translation via Co-transcriptional N6-adenosine Methylation. Cell 169, 326–
337.e12.
Stern-Ginossar, N., Thompson, S.R., Mathews, M.B., and Mohr, I. (2019). 
Translational Control in Virus-Infected Cells. Cold Spring Harb. Perspect. 
Biol. 11, a033001.
Su, A.I., Pezacki, J.P., Wodicka, L., Brideau, A.D., Supekova, L., Thimme, R., 
Wieland, S., Bukh, J., Purcell, R.H., Schultz, P.G., and Chisari, F.V. (2002).Genomic analysis of the host response to hepatitis C virus infection. Proc.
Natl. Acad. Sci. USA 99, 15669–15674.
Sumpter, R., Jr., Loo, Y.M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon,
S.M., and Gale, M., Jr. (2005). Regulating intracellular antiviral defense and
permissiveness to hepatitis C virus RNA replication through a cellular RNA heli-
case, RIG-I. J. Virol. 79, 2689–2699.
Supek, F., Bosnjak, M., Skunca, N., and Smuc, T. (2011). REVIGO summarizes
and visualizes long lists of gene ontology terms. PLoS ONE 6, e21800.
Suthar, M.S., Aguirre, S., and Fernandez-Sesma, A. (2013). Innate immune
sensing of flaviviruses. PLoS Pathog. 9, e1003541.
Takashima, K., Oshiumi, H., Takaki, H., Matsumoto, M., and Seya, T. (2015).
RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and at-
tenuates the innate immune response. Cell Rep. 11, 192–200.
Tan, B., Liu, H., Zhang, S., da Silva, S.R., Zhang, L., Meng, J., Cui, X., Yuan, H.,
Sorel, O., Zhang, S.W., et al. (2018). Viral and cellular N6-methyladenosine and
N6,20-O-dimethyladenosine epitranscriptomes in the KSHV life cycle. Nat.
Microbiol. 3, 108–120.
Thrift, A.P., El-Serag, H.B., and Kanwal, F. (2017). Global epidemiology and
burden of HCV infection and HCV-related disease. Nat. Rev. Gastroenterol.
Hepatol. 14, 122–132.
Tirumuru, N., Zhao, B.S., Lu, W., Lu, Z., He, C., and Wu, L. (2016). N(6)-meth-
yladenosine of HIV-1 RNA regulates viral infection and HIV-1 Gag protein
expression. eLife 5, e15528.
Tsai, K., Courtney, D.G., and Cullen, B.R. (2018). Addition of m6A to SV40 late
mRNAs enhances viral structural gene expression and replication. PLoS
Pathog. 14, e1006919.
Vaquero-Garcia, J., Barrera, A., Gazzara, M.R., González-Vallinas, J., Lahens,
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N6-methyladenosine 50 monophosphate salt Santa Cruz Biotech. Cat# sc-215524; CAS: 81921-35-9
Human IFN-b PBL Assay Science Cat# 11415-1
TRIzol Thermo Fisher Sci. Cat# 15596026
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TRIzol LS Thermo Fisher Sci. Cat# 10296010
NP-40 Thermo Fisher Sci. Cat# 85124
n-Dodecyl-b-D-maltoside (DDM) Chem-Impex Cat# 21950
Puromycin Sigma-Aldrich Cat# P8833
Cycloheximide Sigma-Aldrich Cat# 7698
Blasticidin Thermo Fisher Sci. Cat# R21001
Recombinant RNaseIN RNase inhibitor Promega Cat# N2511
Protease inhibitor Sigma-Aldrich Cat# P8340
Phosphatase inhibitor Thermo Fisher Sci. Cat# 78426
NotI-HF New England Biolabs Cat# R3189
PmeI New England Biolabs Cat# R0560
XhoI New England Biolabs Cat# R0146
NruI-HF New England Biolabs Cat# R3192
BamHI-HF New England Biolabs Cat# R3136
BglII New England Biolabs Cat# R0144
Hoescht 33342 Thermo Fisher Sci. Cat# 62249
Actinomycin D Sigma-Aldrich Cat# A9415
2X Laemmli sample buffer Bio-Rad Cat# 161-0737
Nuclease P1 Sigma-Aldrich Cat# N8630
Antarctic phosphatase New England Biolabs Cat# M0289
Protein G Dynabeads Thermo Fisher Sci. Cat# 10004D
FLAG M2 conjugated beads Sigma-Aldrich Cat# M8823; RRID: RRID:AB_2637089
35S PerkinElmer Cat# NEG772007MC
Opti-MEM I reduced serum medium Thermo Fisher Sci. Cat# 31985070
Methionine/cysteine-free DMEM Sigma-Aldrich Cat# D0422
Critical Commercial Assays
N6-methyladenosine enrichment kit New England Biolabs Cat# E1610S
Dynabeads mRNA purification kit Thermo Fisher Sci. Cat# 61006
NEBNext rRNA depletion kit New England Biolabs Cat# E6310S
Power SYBR Green PCR master mix Thermo Fisher Sci. Cat# 4367659
Dual luciferase reporter assay system Promega Cat# E1960
CellTiter-Glo luminescent cell viability assay Promega Cat# G7571
Protein assay dye-reagent concentrate Bio-Rad Cat# 5000006
iScript cDNA synthesis kit Bio-Rad Cat# 1708891BUN
Superscript III enzyme Thermo Fisher Sci. Cat# 18080044
InFusion HD cloning kit Takara Bio Cat# 639650
Quik-change Lightning SDM kit Agilent Cat# 210518
RNA fragmentation reagent Thermo Fisher Sci Cat# AM8740
Trans-IT mRNA transfection reagent Mirus Cat# MIR2225
FuGENE 6 transfection reagent Promega Cat# E2691
Lipofectamine RNAiMAX transfection reagent Thermo Fisher Sci. Cat# 13778150
CloneAmp HiFi PCR premix Clontech Cat# 639298
VIP peroxidase substrate kit Vector Laboratories Cat# SK-4600
TURBO DNase Thermo Fisher Sci Cat# AM2239
Deposited Data
MeRIP-seq of mRNA from DENV, ZIKV,
WNV, and HCV infected (MOI 1, 48 h) and
uninfected Huh7 cells
This study GEO: GSE130891
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MeRIP-seq of mRNA from HCV PAMP treated
(8 h), TG treated (16 h) and untreated Huh7 cells
This study GEO: pending
Experimental Models: Cell Lines
Huh7 Gift of Dr. Michael Gale, Jr.
(Sumpter et al., 2005)
RRID: RRID:CVCL_0336
Huh7.5 Gift of Dr. Michael Gale, Jr.
(Sumpter et al., 2005)
RRID: RRID:CVCL_7927
293T ATCC ATCC Cat# CRL-3216; RRID:CVCL_0063
Vero ATCC ATCC Cat# CCL-81; RRID:CVCL_0059
C6/36 ATCC ATCC Cat# CRL-1660; RRID:CVCL_Z230
Huh7 IRF3 KO Vazquez et al., 2019 N/A
Huh7 FLAG-GFP Gokhale et al., 2016 N/A
Huh7 FLAG-YTHDF1 Gokhale et al., 2016 N/A
Huh7 FLAG-RIOK3-1 This study N/A
Huh7 FLAG-RIOK3-2 This study N/A
Huh7 FLAG-CIRBP-S-1 This study N/A
Huh7 FLAG-CIRBP-S-2 This study N/A
Huh7 FLAG-CIRBP-L-1 This study N/A
Huh7 FLAG-CIRBP-L-2 This study N/A
Huh7 m6A-null RLuc – RIOK3 30UTR WT This study N/A
Huh7 m6A-null RLuc – RIOK3 30UTR m6A-mut This study N/A
Oligonucleotides
Oligonucleotides for qRT-PCR Table S4 N/A
Oligonucleotides and gBocks for Cloning Table S4 N/A
Oligonucleotides for siRNA Table S4 N/A
Recombinant DNA
pLEX-RIOK3 This study N/A
pLEX-CIRBP-S This study N/A
pLEX-CIRBP-L This study N/A
psiCheck2 m6A-null RIOK3-30UTR WT This study N/A
psiCheck2 m6A-null RIOK3-30UTR m6A-mut This study N/A




pcDNA-Blast Kennedy et al., 2015 N/A
psPAX2 Duke Functional Genomics
Core Facility
Addgene plasmid # 12260; RRID:Addgene_12260
pMD2.G Duke Functional Genomics
Core Facility
Addgene Plasmid #12259; RRID:Addgene_12259
Software and Algorithms
ImageStudio LI-COR Biosciences RRID:SCR_013715; https://www.licor.com/bio/
products/software/image_studio_lite
Fiji Schindelin et al., 2012 RRID:SCR_002285 https://fiji.sc
Prism 8.0 Graphpad RRID:SCR_002798; https://www.graphpad.com
STAR Dobin et al., 2013 v2.5.0a, https://github.com/alexdobin/STAR
MACS2 Zhang et al., 2008 v2.1.1.20160309, https://github.com/taoliu/MACS
DESeq2 Love et al., 2014 v1.20.0, https://bioconductor.org/packages/release/
bioc/html/DESeq2.html
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edgeR Robinson et al., 2010 v3.22.3,
https://bioconductor.org/packages/release/bioc/
html/edgeR.html
QNB Liu et al., 2017a v1.1.11, https://cran.r-project.org/src/contrib/
Archive/QNB/
CovFuzze Imam et al., 2018 v0.1.3, https://github.com/al-mcintyre/CovFuzze
gProfiler Reimand et al., 2016 ve95_eg42_p13_f6e58b9, https://biit.cs.ut.ee/
gprofiler/gost
REVIGO Supek et al., 2011 http://revigo.irb.hr/
HOMER Heinz et al., 2010 v4.9.1, http://homer.ucsd.edu/homer/motif/
fgsea Sergushichev, 2016 v1.8.0, https://bioconductor.org/packages/release/
bioc/html/fgsea.html
UpSetR Conway et al., 2017 v1.3.3, https://CRAN.R-project.org/package=UpSetRLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stacy M.
Horner (stacy.horner@duke.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
Huh7 and Huh-7.5 cells (gift of Dr. Michael Gale Jr., University of Washington (Sumpter et al., 2005)), Huh7 IRF3 KO cells (Vazquez et
al., 2019), 293T cells (ATCC: CRL-3216) Vero cells (ATCC: CCL-81), C6/36 (ATCC: CRL-1660) were grown in Dulbecco’smodification
of Eagle’s medium (DMEM; Mediatech) supplemented with 10% fetal bovine serum (HyClone), 25 mM HEPES (Thermo Fisher), and
1X non-essential amino acids (Thermo Fisher), referred to as complete DMEM (cDMEM). Huh7 and Huh-7.5 cells were verified using
the Promega GenePrint STR kit (DNA Analysis Facility, Duke University), and cells were verified as mycoplasma free by the LookOut
Mycoplasma PCR detection kit (Sigma-Aldrich).
Viruses
Infectious stocks of a cell culture-adapted strain of genotype 2A JFH1 HCV were generated and titered in Huh-7.5 cells by focus-
forming assay (FFA), as described (Aligeti et al., 2015). DENV2-NGC (Sessions et al., 2009), ZIKV-PR2015 (Quicke et al., 2016),
and WNV-NY2000 (Diamond et al., 2003) stocks were prepared in C6/36 insect cells and titered in Vero cells, as described. For viral
infections, cells were incubated in a low volume of cDMEM containing virus at a multiplicity of infection (MOI) of 1 for 2-3 h (except
when otherwise stated), following which cDMEMwas replenished. Cells were infected for 48 h unless otherwise described. To quan-
tify virus, cellular supernatants were analyzed by FFA.
METHOD DETAILS
MeRIP-seq
Huh7 cells seeded in 15 cm plates were infected with DENV, ZIKV, WNV, or HCV (MOI 1) or left uninfected (mock-infected). At 48 h
post-infection, total RNA was extracted using TRIzol (Thermo Fisher) and treated with TURBO DNase I (Thermo Fisher). mRNA was
purified from 200 mg total RNA from each sample using the Dynabeads mRNA purification kit (Thermo Fisher) and concentrated by
ethanol precipitation. mRNA was fragmented using the RNA Fragmentation Reagent (Thermo Fisher) for 15 min and purified by
ethanol precipitation. MeRIP was performed using EpiMark N6-methyladenosine Enrichment kit (NEB) according to the manufac-
turer’s recommendations with the following modifications. Briefly, 25 mL Protein G Dynabeads (Thermo Fisher) per sample were
washed three times in MeRIP buffer (150 mM NaCl, 10 mM Tris-HCl [pH 7.5], 0.1% NP-40), and incubated with 1 mL anti-m6A anti-
body for 2 h at 4C with rotation. After washing three times with MeRIP buffer, anti-m6A conjugated beads were incubated with pu-
rified mRNA with rotation at 4C overnight in 300 mL MeRIP buffer with 1 mL RNase inhibitor (recombinant RNasin; Promega). 10% of
themRNA sample was saved as the input fraction. Beads were thenwashed twice with 500 mLMeRIP buffer, twice with low salt wash
buffer (50 mMNaCl, 10 mM Tris-HCl [pH 7.5], 0.1% NP-40), twice with high salt wash buffer (500 mMNaCl, 10 mM Tris-HCl [pH 7.5],
0.1% NP-40), and once again with MeRIP buffer. m6A-modified RNA was eluted twice in 100 mL of MeRIP buffer containing 5 mM
m6A salt (Santa Cruz Biotechnology) for 30 min at 4C with rotation. Eluates were pooled and concentrated by ethanol purification.
RNA-seq libraries were prepared from both eluate and 10% input mRNA using the TruSeq mRNA library prep kit (Illumina), subjected 
to quality control (MultiQC), and sequenced on the HiSeq 4000 instrument.
MeRIP-qRT-PCR
For MeRIP-qRT-PCR, total RNA was harvested from uninfected and infected Huh7 and Huh7 IRF3 KO cells seeded in 10 cm plates or 
6-well plates at 48 h post-infection. For ER-stress induction, cells seeded in 6-well plates were treated with 500 nM thapsigargin 
(Tocris) for 16 h. For interferon treatment, cells seeded in 6-well plates were incubated with 100 U/mL human IFN-b (PBL Assay Sci-
ence) for 24 h. HCV PAMP was prepared by in vitro transcription, as described (Beachboard et al., 2019; Saito et al., 2008). 2.5 mg of  
HCV PAMP RNA was transfected into cells seeded in 6-well plates for 8 h using the Mirus mRNA transfection kit. At the indicated time 
points for each experiment, RNA was extracted and MeRIP-qRT-PCR was performed like MeRIP-seq with some differences. Spe-
cifically, total RNA was prepared from cells using TRIzol, and diluted to equivalent concentrations. Then, 20-50 mg total RNA was 
fragmented for 3 min, purified by ethanol precipitation, and resuspended in 30 mL water. 0.1 fmol of positive control (m6A-modified 
Gaussia luciferase RNA) and negative control (unmodified Cypridina luciferase RNA) spike-ins supplied with the EpiMark N6-meth-
yladenosine Enrichment kit were added to each sample. Following MeRIP as described above, eluates were concentrated by ethanol 
precipitation. 1 mL input and the entire IP fractions were reverse transcribed using the iScript cDNA synthesis kit (BioRad) and sub-
jected to qRT-PCR. Primer sequences are supplied in Table S4. Relative m6A level for each transcript was calculated as the percent 
of input in each condition normalized to that of the respective positive control spike-in. Fold change of enrichment was calculated 
with mock samples normalized to 1.
qRT-PCR
The iScript cDNA synthesis kit (Bio-Rad) was used for reverse transcription of total RNA samples. qRT-PCR was performed using the 
Applied Biosystems QuantStudio 6 Flex real-time PCR instrument. To measure relative abundance of CIRBP isoforms, total RNA was 
reverse transcribed with the Superscript III enzyme (Invitrogen) using a gene specific primer. qRT-PCR was performed using specific 
primers that detect CIRBP isoforms. The expression of each isoform was normalized to invariant region of CIRBP. Primer sequences 
are provided in Table S4.
Immunoblotting
Cell lysates were prepared in a modified RIPA buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 0.5% sodium deoxycholate, and 1% Triton 
X-100) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitor cocktail II (Millipore), and clarified by 
centrifugation. Protein concentration was determined by Bradford assay (Bio-Rad). 5-15 mg of protein was resolved by SDS/PAGE 
and transferred to nitrocellulose membranes using the Trans-Blot Turbo System (Bio-Rad). Membranes were blocked in 5% milk in 
phosphate buffered saline with 0.1% Tween (PBS-T) and incubated with the relevant primary antibodies. After washing three 
times with PBS-T, membranes were incubated with species-specific horseradish peroxidase-conjugated antibodies (Jackson 
ImmunoResearch, 1:5000) or fluorescent antibodies (LI-COR, IRDye 800, 1:5000). Chemiluminescence (Clarity ECL, Bio-Rad) or fluo-
rescence was detected on a LI-COR Odyssey Fc instrument and analyzed using the ImageStudio software. The following antibodies 
were used for immunoblot: anti-METTL3 (Novus Biologicals, 1:1000), anti-METTL14 (Sigma-Aldrich, 1:5000), anti-FTO (Abcam, 
1:1000), anti-YTHDF1 (Proteintech, 1:1000), anti-YTHDF2 (Proteintech, 1:1000), anti-YTHDF3 (Sigma-Aldrich, 1:1000), anti-ALKBH5 
(Sigma-Aldrich, 1:1000), anti-WTAP (Proteintech, 1:1000) anti-FLAG M2 (Sigma-Aldrich, 1:5000), anti-tubulin (Sigma-Aldrich, 
1:5000), anti-HCV NS5A (clone 9E10, gift of Charles Rice, Rockefeller University (Lindenbach et al., 2005), 1:1000), anti-RIOK3 (Pro-
teintech, 1:1000), anti-CIRBP (Proteintech 1:1000), anti-DENV NS3 (GeneTex, 1:1000), anti-ZIKV NS3 (GeneTex, 1:1000), anti-HCV 
NS4A (Genscript custom (Horner et al., 2011)), 1:1000), anti-eIF2a (Cell Signaling, 1:1000), anti-phospho-eIF2a (Cell Signaling, 
1:1000), anti-GADD34 (Proteintech, 1:1000), anti-HSPA5 (Cell Signaling, 1:1000), anti-H2A.X (Cell Signaling, 1:1000), anti-U170K 
serum (gift of Dr. Jack Keene, Duke University, (Query and Keene, 1987), 1:1000).
FLAG-YTHDF RNA immunoprecipitation
Generation of Huh7 cells stably expressing FLAG-GFP or FLAG-YTHDF1 was described previously (Gokhale et al., 2016). Cells 
seeded in 6-well plates were infected with DENV, ZIKV, or HCV (MOI 1). At 48 h post-infection cells were harvested by trypsinization 
and lysed in polysome lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES [pH 7.0], 0.5% NP-40), supplemented with protease 
inhibitor cocktail (Sigma-Aldrich) and RNase inhibitor (RNasin), and cleared by centrifugation. Protein was quantified by Bradford 
assay, and 200 mg ribonucleoprotein complexes were immunoprecipitated with M2 anti-FLAG conjugated magnetic beads 
(Sigma-Aldrich) overnight at 4C with rotation in NT2 buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40). 
Beads were washed five times in ice-cold NT2 buffer. Protein for immunoblotting was eluted from ten percent of beads by boiling 
in 2X Laemmli sample buffer (Bio-Rad). RNA was extracted from ninety percent of beads using TRIzol reagent (Thermo Fisher). Equal 
volumes of eluted RNA were used for cDNA synthesis, quantified by qRT-PCR, and normalized to RNA levels in input samples. Fold 
enrichment was calculated with FLAG-GFP and mock samples set as 1.
siRNA treatment and viral infectivity assays
Cells seeded in 24-well plates were transfectedwith siRNA against intended targets (QIAGEN, sequences provided in Table S4) using
Lipofectamine RNAiMAX (Thermo Fisher) according to the manufacturer’s recommendation. At 24 h post-transfection, cells were
infected with DENV, ZIKV, and HCV (MOI 0.2). At 48 (targeted siRNA screen) or 72 (RIOK3 and CIRBP depletion) h post-infection,
virus titer in the supernatant was measured by FFA. Serial dilutions of supernatants were used to infect naive Vero (DENV and
ZIKV) or Huh-7.5 (HCV) cells in triplicate wells of a 48-well plate. At 72 h post-infection, cells were fixed in cold 1:1 methanol:acetone
and immunostained with 4G2 antibody purified in the lab from a hybridoma (for DENV and ZIKV, 1:2000), or anti-HCV NS5A (1:2000).
Following binding of horseradish peroxidase conjugated secondary antibody (1:1000; Jackson ImmunoResearch), infected foci were
visualized with the VIP Peroxidase Substrate Kit (Vector Laboratories) and counted at 40X magnification. Titer was calculated using
the following formula: (dilution factor x number of foci x 1000) / volume of infection (ml), resulting in units of focus forming units / mL
(FFU/mL). Depletion of siRNA targets was confirmed by qRT-PCR (primer sequences in Table S4). Cellular viability after siRNA treat-
ment was measured by the Cell-Titer Glo assay (Promega) according to the manufacturer’s recommendation.
For testing the effect of YTHDF1 on RIOK3 translation, cells plated in 6-well plates were transfected with siRNAs against YTHDF1
(QIAGEN, Table S4) at 24 and 48 h following seeding. 24 h after the second round of transfection, cells were infected DENV, and
lysates were harvested at 48 h post-transfection and subjected to immunoblotting.
Quantification of infection by immunofluorescence
To measure percent of cells infected following viral infection, Huh7 cells seeded in 96-well plates were infected with DENV, ZIKV,
WNV, or HCV (MOI 1). Cells were fixed in cold 1:1 methanol:acetone at the indicated h post-infection, and immunostained with
4G2 antibody (DENV, ZIKV, WNV) or anti-HCV NS5A. Following binding of AlexaFluor 488-conjugated secondary antibody (Thermo
Fisher) and nuclear staining with Hoechst (Thermo Fisher), cells were imaged using the Cellomics Arrayscan VTI robotic microscope
at the Duke Functional Genomics Core Facility. The percentage of infected cells was determined by measuring cells stained for viral
antigen relative to the total number of nuclei.
Immunofluorescence assay for CIRBP localization
Huh7 cells stably expressing FLAG-tagged CIRBP-S and CIRBP-L were plated in 4-well chamber slides (Millipore) and infected
with the indicated virus (MOI 1). At 48 h post-infection, cells were fixed in 4% paraformaldehyde, permeabilized with 0.2% Triton
X-100 (Sigma-Aldrich), and immunostained with anti-FLAG (Sigma-Aldrich, 1:1000) antibody, or antibody against viral antigens
(4G2 for DENV and ZIKV (1:1000); anti-NS5A (1:1000) for HCV). Following treatment with AlexaFluor dye-conjugated secondary
antibodies (Thermo Fisher) and the nuclear stain Hoescht, coverslips were mounted with ProLong Gold (Thermo Fisher) and imaged
on a Leica DM4 B fluorescence microscope using a 63X objective. Images were processed with the Fiji software (Schindelin
et al., 2012).
Cell fractionation
Fractionation of cells to isolate chromatin-associated RNA was performed as described (Ke et al., 2017). Briefly, cells were collected
from 10 cm plates by trypsinization, lysed in 200 mL cytoplasmic lysis buffer (10 mM Tris-HCL [pH 7.4], 150 mM NaCl, 0.15% NP-40)
on ice for 5 min, and passed through 500 ml 24% sucrose cushion by centrifugation at 12000 xG for 10 min at 4C. The supernatant
(cytoplasmic fraction) was then removed and the nuclear pellet was rinsed twice with cold phosphate buffered saline (PBS). The nu-
clear pellet was resuspended in 100 mL ice cold glycerol buffer (20 mM Tris-HCL [pH 7.4], 75 mM NaCl, 0.5 mM EDTA, 1 mM DTT,
125 mMPMSF, 50% glycerol). 100 mL nuclear lysis buffer (10 mMHEPES [pH 7.4], 1 mMDTT, 7.5 mMMgCl2, 0.2 mMEDTA, 300 mM
NaCl, 1 M urea, 1%NP-40) was added to the suspension, followed by brief vortexing, and incubation on ice for 2 min. Samples were
centrifuged for 2 min at 4C at 12000 xG and the supernatant (nuclear fraction) was removed. The chromatin pellet was rinsed twice
with cold PBS, resuspended in 50 mL DNase I buffer with 2 U Turbo DNase I (Invitrogen), and incubated at 37C for 30 min. RNA was
then extracted from the chromatin fraction using TRIzol reagent and subjected to MeRIP-qRT-PCR. The cytoplasmic, nuclear, and
chromatin fractions were subjected to immunoblotting to analyze fractionation.
For nuclear/cytoplasmic fractionation to investigate mRNA export, uninfected and infected (MOI 1) cells grown in 10 cm plates
were harvested by trypsinization and lysed in 200 mL lysis buffer (10mM Tris-HCl [pH 7.4], 140 mM NaCl, 1.5 mM MgCl2, 10 mM
EDTA, 0.5% NP-40) on ice for 5 min. Following centrifugation at 12000 xG at 4C for 5 min, the supernatant (cytoplasmic fraction)
was collected, and the nuclear pellet was rinsed twice with lysis buffer. RNA was extracted from cytoplasmic and nuclear pellets us-
ing TRIzol reagent and analyzed by qRT-PCR.
Measurement of RNA stability
Cells plated in 24-well plates were infected with the indicated virus (MOI 1). At 36 h post-infection, media was changed to cDMEM
containing 1 mM Actinomycin D (Sigma-Aldrich). RNA was extracted from cells at the indicated time points post-treatment using
TRIzol reagent and analyzed by qRT-PCR. Data were normalized as the percent of RNA remaining at each time point after treatment,
relative to that at the time of treatment.
Polysome profiling
Mock- and DENV-infected (MOI 1) Huh7 cells plated in 10 cm plates were harvested by trypsinization at 48 h post infection following a 
10 min pulse with cycloheximide (0.2 mM; Sigma-Aldrich) and were lysed in cytoplasmic lysis buffer (200 mM KCl, 25 mM HEPES 
pH 7.0, 10 mM MgCl2, 2% n-Dodecyl b-D-maltoside (DDM; Chem-Impex), 0.2 mM cycloheximide (Sigma-Aldrich), 1 mM DTT, 
40 U RNaseIn) for 15 min on ice. Following clarification, lysates were ultracentrifuged on 15%–50% sucrose gradients prepared 
in polysome gradient buffer (200 mM KCl, 25 mM HEPES pH 7.0, 15 mM MgCl2, 1 mM DTT, 0.2 mM cycloheximide) at 35,000 xG 
for 3.5 h at 4C. Following ultracentrifugation, 16 fractions were collected from each sample using a BioComp Piston Gradient 
Fractionator instrument fitted with a TRIAX flow cell to measure absorbance. RNA was extracted from each fraction using TRIzol 
LS reagent (Thermo Fisher), and RNA quality was checked on a 1% agarose gel. Following cDNA synthesis using the iScript 
cDNA synthesis kit, qRT-PCR was performed using primers specific for the long and short isoforms of CIRBP.
RIOK3 and CIRBP cloning and stable cell lines
All primer sequences used for cloning are provided in Table S4. RIOK3 (GenBank: NM_003831.4), as well as both long (GenBank: 
NM_001300829) and short (GenBank: NM_001280) isoforms of CIRBP, were cloned by PCR (HiFi PCR premix, Clontech) from 
cDNA from Huh7 cells prepared with the Superscript III RT kit (Thermo Fisher) using the oligo(dT)20 primer. PCR products were in-
serted into pLEX-FLAG lentiviral vector between the NotI and XhoI sites using the InFusion HD cloning kit (Takara Bio) to generate 
constructs with N-terminal FLAG tags. Lentivirus was produced from 293T cells transfected with pLEX vectors and packaging plas-
mids psPAX2 and pMD2.G (provided by Duke Functional Genomics Facility). Huh7 cells were transduced by these lentiviruses and 
stable cell lines expressing FLAG-RIOK3, FLAG-CIRBP-S, and FLAG-CIRBP-L were selected using puromycin (2 mg/mL; Sigma-Al-
drich). Single cell clones were obtained by serial dilution and verified by immunoblotting. Cell lines were maintained in cDMEM con-
taining 1 mg/mL puromycin.
Reporter cloning and luciferase assays
All primer and gBlock sequences are provided in Table S4. To generate m6A null RIOK3 reporters, the Renilla and Firefly luciferase 
genes in psiCheck2 plasmid (Promega) were first replaced by constructs with synonymous mutations in putative m6A sites (obtained 
as IDT gBlocks). The wild type RIOK3 30 UTR was cloned from Huh7 cDNA (GenBank: NM_003831.4) and inserted after the m6A null 
Renilla luciferase gene in the multiple cloning site of psiCheck2 between XhoI and NotI using the InFusion HD kit. m6A-mut RIOK3 30 
UTR (in which all putative m6A sites were mutated from A to T) was obtained as a gBlock and also inserted between these restriction 
sites. WT and m6A-mut RIOK3 reporter plasmids along with the pcDNA-Blast plasmid (Kennedy et al., 2015) were linearized using 
BamHI and BglII respectively, purified by ethanol precipitation and co-transfected into Huh7 cells in 6-well plates (90 ng reporter, 
10 ng pcDNA-Blast) using FuGENE 6 transfection reagent (Promega). Cells were selected with blasticidin (0.2 mg/mL; Thermo Fisher) 
and single cell clones stably expressing WT and m6A-mut reporters were isolated. For MeRIP-qRT-PCR of reporter RNA, WT and 
m6A-mut expressing cells were plated in 6-well plates, infected with the indicated virus (MOI 1), and RNA was extracted using TRIzol 
at 48 h post-infection. Following MeRIP as described, qRT-PCR was performed to discriminate reporter RNA using a forward primer 
within the Renilla luciferase gene and a reverse primer in the RIOK3 30 UTR. For luciferase assays, WT and m6A-mut expressing cells 
in 24-well plates were infected with the indicated virus (MOI 1) and dual luciferase assay (Promega) was performed at 48 h post-infec-
tion according to the manufacturer’s instructions. Data was normalized as the value of Renilla luminescence divided by Firefly lumi-
nescence, and values for mock-infected cells were set as 1.
To generate CIRBP splicing reporters, CIRBP exon 5 – 30 UTR (Hg38;chr19:127553-1273172) was amplified by PCR from genomic 
DNA. A fragment of m6A null Renilla luciferase beyond the NruI site and up to the stop codon was amplified by PCR with overlapping 
ends with Renilla luciferase (50; before the NruI site) and the CIRBP fragment (30). These fragments were inserted into NruI-XhoI di-
gested psiCheck2 m6A null plasmid using the InFusion HD kit. m6A-mut CIRBP reporter was generated by mutating the essential C in 
the m6A site synonymously to T using two rounds of site-directed mutagenesis with the QuikChange Lightning kit (Agilent).
35S pulse-labeled immunoprecipitation
Huh7 cells seeded in 10 cm plates were infected with DENV (MOI 1) or left uninfected. At 45 h post-infection, media was removed and 
3 mL warm methionine/cysteine-free DMEM was added to plates. After 15 min of incubation, 3 mL methionine/cysteine-free DMEM 
containing 100 mCi 35S (Perkin Elmer) was added. Cells were harvested at 3 h post-treatment and lysed in RIPA buffer. 300 mg protein 
was incubated with 4 mg anti-RIOK3 antibody (Proteintech) or normal rabbit IgG (Cell Signaling) in 300 mL RIPA buffer overnight at 4C 
with rotation. Antibody-protein complexes were then incubated with 40 mL pre-washed protein G Dynabeads (Thermo Fisher) for 2 h. 
Protein was eluted from beads in 2X Laemmli buffer. Eluates were resolved by SDS/PAGE. Gels were fixed in solution containing 50%
methanol and 10% acetic acid, dried, and subjected to autoradiography on film.
LC-MS/MS for m6A/A determination
mRNA was purified from 200 mg total RNA extracted from uninfected and infected Huh7 cells (MOI 1, 48 h post-infection) using one 
round of polyA selection (Dynabeads mRNA purification kit; Thermo Fisher) and one round of rRNA depletion (NEBNext rRNA deple-
tion kit, NEB). After ethanol precipitation, purified mRNA was digested into mononucleotides with nuclease P1 (Sigma-Aldrich, 2 U) in 
buffer containing 25 mM NaCl and 2.5 mM ZnCl2 for 2 h at 37C, followed by incubation with Antarctic Phosphatase (NEB, 5 U) for an
additional 2 h at 37C. Nucleosides were separated and quantified using UPLC-MS/MS as previously described, except acetic acid
was used in place of formic acid (Basanta-Sanchez et al., 2016).
QUANTIFICATION AND STATISTICAL ANALYSIS
Western blot images were acquired and analyzed using Li-Cor Image Studio. Microscopy pictures were processed in Fiji. Fig-
ure panels were processed and organized using Adobe Illustrator CC. qRT-PCR and MeRIP-qRT-PCR data was analyzed using
Microsoft Excel. Graphpad Prism 8 was used to generate graphs, to determine the mean, standard deviation or standard error,
and to perform statistical analyses, as described in the figure legends.
Data analysis for MeRIP-seq and RNA-seq
Reads were aligned using STAR (Dobin et al., 2013) to the human reference genome (hg38), combined with the appropriate virus
genome for each infected sample. Differential gene expression between infected and uninfected samples was compared using
DESeq2 (Love et al., 2014). UpSet plots of the intersects between genes regulated with individual viruses were generated using
UpSetR (Conway et al., 2017). Gene ontology for RNA-seq changes in Figure S1D was analyzed using gProfiler, with redundant
GO terms collapsed using REVIGO (Reimand et al., 2016; Supek et al., 2011). For gProfiler, upregulated genes with Log2FC R 2
and adjusted p value < 0.05 with all viruses were considered. There were very few consistently downregulated genes at
Log2FC % 2 (particularly for ZIKV), so we expanded our set to genes with smaller Log2FC % 0.5, downregulated by DENV,
HCV, and WNV infection. For REVIGO, we allowed similarity of up to 0.5, with semantic similarity calculated using SimRel. Adjusted
p values were provided for the REVIGO calculations. Gene set enrichment analyses using fgsea in R showed similar differentially
regulated pathways as gProfiler (Sergushichev, 2016). ‘‘Infection-annotated’’ genes and peakswere summarized for Figure 1B based
on gene inclusion in ‘‘Infectious disease,’’ ‘‘Unfolded Protein Response (UPR),’’ ‘‘Interferon Signaling,’’ and ‘‘Innate Immune System’’
Reactome pathways from fgsea.
We called m6A peaks fromMeRIP-seq using MACS2 (Zhang et al., 2008) and used all peaks detected in at least two replicates for
further analysis. Motif enrichment was calculated using HOMER for Figure 1C (Heinz et al., 2010). Metagene plots for methylated
DRACH motifs were plotted using a custom script. DRACH motifs were considered methylated if detected under m6A peaks in at
least 2 biological replicates. Relative positions of m6A peaks within genes are based on the transcripts with the highest mean
coverage per gene, as calculated with kallisto (Bray et al., 2016).
We identified m6A peaks changes using a generalized linear model (adapted from (Park et al., 2014)), and the QNB program (Liu
et al., 2017a). In brief (see Park et al., 2014 or McIntyre et al., 2019 for more details), a generalized linear model following the equation
logmij = b0i + bIPiXIPj + bVIRiXVIRj + bIP:VIRiXIP:VIRj + logNj
was fit with the following parameters for each peak i and sample j: XIP = 1 for immunoprecipitated samples and 0 for input samples,
and XVIR = 1 for infected samples and 0 for mock. A library size parameter was included for normalization (N) with edgeR (Robinson
et al., 2010). The full model was compared to a reduced model without the infection:IP interaction term using a likelihood ratio test of
the difference between deviances, implemented through DESeq2 (Love et al., 2014) or edgeR. To control for changes in gene expres-
sion, changes in gene expression were subtracted from changes in IP peak reads for significantly modified peaks from DESeq2,
edgeR, and QNB, with a threshold for absolute difference in Log2 fold change ofR 1. Significant peaks were further filtered for loca-
tion within exons, DRACH motif content, and mean input read counts of R 10 to produce the final set of 58 peak changes.
Peaks of interest were plotted for visual evaluation using CovFuzze (https://github.com/al-mcintyre/CovFuzze) (Imam et al., 2018).
DATA AND CODE AVAILABILITY
The raw data fromMeRIP-seq analysis of uninfected, HCV PAMP, TG-treated, and infected Huh7 cells have been deposited and are
available through GEO: GSE130891 and GEO: GSE138730.
